Atossa Therapeutics Stock Gross Profit
| YAG2 Stock | EUR 1.20 0.01 0.83% |
Atossa Therapeutics fundamentals help investors to digest information that contributes to Atossa Therapeutics' financial success or failures. It also enables traders to predict the movement of Atossa Stock. The fundamental analysis module provides a way to measure Atossa Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Atossa Therapeutics stock.
Atossa |
Atossa Therapeutics Company Gross Profit Analysis
Atossa Therapeutics' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, Atossa Therapeutics reported 0.0 of gross profit. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The gross profit for all Germany stocks is 100.0% higher than that of the company.
Atossa Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Atossa Therapeutics' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Atossa Therapeutics could also be used in its relative valuation, which is a method of valuing Atossa Therapeutics by comparing valuation metrics of similar companies.Atossa Therapeutics is currently under evaluation in gross profit category among its peers.
Atossa Fundamentals
| Return On Equity | -0.18 | |||
| Return On Asset | -0.11 | |||
| Current Valuation | (59.13 M) | |||
| Shares Outstanding | 126.62 M | |||
| Shares Owned By Insiders | 0.04 % | |||
| Shares Owned By Institutions | 20.65 % | |||
| Price To Book | 0.64 X | |||
| EBITDA | (20.5 M) | |||
| Net Income | (20.61 M) | |||
| Cash And Equivalents | 131.49 M | |||
| Cash Per Share | 1.04 X | |||
| Total Debt | 1.22 K | |||
| Current Ratio | 58.94 X | |||
| Book Value Per Share | 0.97 X | |||
| Cash Flow From Operations | (16.47 M) | |||
| Earnings Per Share | (0.17) X | |||
| Target Price | 7.75 | |||
| Beta | 1.27 | |||
| Market Capitalization | 88.42 M | |||
| Total Asset | 141.26 M | |||
| Net Asset | 141.26 M |
About Atossa Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Atossa Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Atossa Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Atossa Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Atossa Stock
Atossa Therapeutics financial ratios help investors to determine whether Atossa Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Atossa with respect to the benefits of owning Atossa Therapeutics security.